| Title | [Acute retinal necrosis from the virologist's perspective.] | | Author(s) | Rautenberg P, Grančičova L, Hillenkamp J, Nölle B, Roider JB, Fickenscher H | | Institution | Institut für Infektionsmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus 32, 24105, Kiel, Deutschland, rautenberg@infmed.uni-kiel.de. | | Source | Ophthalmologe 2009 Oct 18. | | Abstract | Acute retinal necrosis occurs in approximately one per million persons per year and is caused in approximately 70% of the cases by the varicella zoster virus or in about 30% of the cases by herpes simplex virus. The early diagnosis is primarily based on virus-specific polymerase chain reaction in fluid from the anterior chamber or vitreous humor and can be supported by the determination of specific antibody titers from fluid and serum. Virus detection provides the basis for early causative therapy which limits disease progression and risk of complications. Retinal infections by varicella zoster virus or herpes simplex virus are treated with aciclovir, ganciclovir, or famciclovir. Ganciclovir and valganciclovir are used for the therapy of retinal cytomegalovirus infections. In the case of resistance development, foscarnet or cidofovir are available as second line antiviral drugs. The early use of specific antiviral agents is a crucial prerequisite for optimized therapy of acute retinal necrosis. | | Language | GER | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19838711 |
|
